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In conclusion, we can learn from these 
new studies that the control of plasma 
calcium and phosphate in CKD patients 
is important in prevention of VC. New 
information about the precise regulators 
of VSMC diﬀerentiation into osteoblastic 
cells is rapidly increasing. Future studies 
should now focus on unraveling the VC 
pathways in detail and investigating the 
exact diﬀerences among the diverse vita-
min D agonists in order to develop new 
drugs that can speciﬁcally treat SHPT 
without inducing VC.
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Hemodialysis vascular access: The 
Achilles’ heel remains
SJ Schwab1
Maintaining vascular access for hemodialysis remains a leading cause 
of patient morbidity. Surveillance and other technologies continue 
to improve, but the goal of dramatically improved AV access patency 
remains elusive.
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Maintenance of access to the circulation 
for hemodialysis continues to be the Achil-
les’ heel of dialysis therapy. This access to 
the circulation is best accomplished by 
the use of arteriovenous (AV) access com-
posed of native AV ﬁstulae and synthetic 
AV ﬁstulae (AV grafts).1–3
Much work in this area has been accom-
plished in the past 20 years. Investigators 
have determined that endothelial and 
fibromuscular hyperplasia of the vein, 
leading to lumen shrinkage or stenosis, is 
the leading cause of failure of mature AV 
access.1–3 These areas of stenosis occur 
predominantly in the area of the vein-
graft anastomosis in AV grafts and areas of 
turbulence or previous cannulation in AV 
access proximal outﬂow veins of AV ﬁs-
tulae and AV grafts (Figure 1). It has been 
established that these stenoses lead to ﬂow 
stasis, thrombosis, and ultimately, if uncor-
rected, AV access abandonment. Conse-
quently, survival of AV access in general 
and AV grafts in particular continues to 
be less than 50% at 3 years of use.1–3 The 
original Kidney Disease Outcomes Quality 
Initiative (KDOQI) panel determined that 
delaying correction of stenoses until after 
thrombosis results in tight stenoses that 
are diﬃcult to correct by either percutane-
ous methods or surgical revision. Taking a 
page from the treatment of coronary artery 
disease, it was reasoned that AV access 
survival would be improved by applica-
tion of prospective surveillance techniques 
followed by early preemptive therapy. The 
published evidence supported this treat-
ment strategy. This strategy (based on the 
sum of the published evidence) continues 
to be the recommendation of the most 
recent KDOQI panel.1 Several trials, how-
ever, have emerged to challenge aspects of 
this theory.
Wijnen and co-investigators from Maas-
tricht, The Netherlands4 (this issue), have 
now advanced another sophisticated AV 
access surveillance technique. Surveil-
lance techniques have evolved from the 
initial description of dynamic venous 
pressure through techniques for measur-
ing static venous pressure to techniques 
for the quantitation of access blood ﬂow.1 
Access blood ﬂow measurements deter-
mined initially by external Doppler ultra-
sound developed as the most sensitive, 
and speciﬁc, but costly of the surveillance 
techniques for the detection of AV access 
stenoses.1 Less expensive AV access ﬂow 
measurements using ultrasound dilu-
tion and other techniques subsequently 
emerged as preferred because of equal 
accuracy, decreased expense, and ease of 
use. Wijnen et al.4 describe a potential 
advance in AV access ﬂow measurement 
techniques. It is clear that our ability to 
detect stenoses is improving with every 
newly described technique. Detection of 
hemodynamically significant stenoses, 
however, is only the ﬁrst step in improv-
ing vascular access patency. The larger 
challenge is in developing a mechanism 
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to reliably treat (or, even better, prevent) 
the stenoses that develop in a manner that 
reliably extends the life of a hemodialysis 
vascular access.
The problem that confronts us in the 
care of our patients is not that surveillance 
can prospectively identify high-grade 
venous stenoses, but rather the emerging 
concern that therapeutic interventions 
on these accesses are less eﬀective than 
needed. It is now clear that sophisticated 
surveillance techniques as described by 
Wijnen et al.4 can reliably detect sub-
critical and critical stenoses. What is now 
challenged is the role of interventions to 
substantially prolong patency once the 
stenoses have been identiﬁed.5 Multiple 
reports by Beathard and several European 
and American investigators suggested that 
percutaneous transluminal angioplasty 
(PTA) was an eﬀective treatment for all 
types of venous stenoses.3,6,7 In a series 
of 536 procedures, Beathard reported an 
initial success rate of 94% in restoring 
patency and a primary patency rate of 
over 60% at 180 days.3 Similar observa-
tions from European and other American 
research supported these contentions.6,7 
Controversially, studies by other estab-
lished investigators successfully detected 
signiﬁcant stenoses but failed to substan-
tially improve outcome parameters fol-
lowing intervention with PTA.8,9 The net 
eﬀect of these studies appears to support 
the concept of surveillance for detecting 
stenoses but calls into question the reli-
ability of PTA as a corrective intervention. 
The concern is that PTA as an intervention 
may be inadequate to maintain patency 
or that PTA (as an explanation for diﬀer-
ing results) is operator dependent for the 
best outcome. Early studies attempting to 
improve AV access patency by the use of 
endovascular stents as an addition to PTA 
were remarkably unsuccessful. Studies 
using stainless steel uncoated stents were 
found to be of value only in elastic sten-
oses, which, in most studies, constituted 
less than 20% of the total.5 Recent pro-
spective observational studies with new 
types of endovascular stents have been 
substantially more promising. A recent 
observational study with self-expand-
ing Nitinol endovascular stents showed 
dramatic improvement in maintaining 
hemodialysis vascular access patency. 
New stents developed with a nickel and 
titanium alloy and coated with Dacron as 
well as cobalt titanium stents appear to be 
more eﬀective in AV access stenosis than 
the previous generation of stents. Vogel et 
al. recently used nickel and titanium alloy 
stents to achieve signiﬁcantly improved 
access patency in prospectively detected 
lesions.10 In like manner, investigators 
from St. Louis obtained dramatically 
improved patency results with nickel and 
titanium alloy stents.5 Self-eluting stents 
that have worked well in small arteries 
remain to be systematically tested in AV 
access veins. Whether these initial obser-
vations with newer stents will bear the test 
of time remains to be determined.
The current controversy does not 
appear to involve surveillance techniques 
for detecting AV access stenoses. Indeed, 
these techniques, as exhibited by Wijnen et 
al.,4 continue to be reﬁned and improved. 
Nor does controversy seem to exist sur-
rounding the fact that resolution of these 
outﬂow stenoses maintains and prolongs 
hemodialysis vascular access patency. At 
issue is the ability of the intervention to 
develop the desired eﬀect of long-term 
reconstitution of the lumen and prevent 
access thrombosis. Major eﬀorts are under 
way to resolve these issues. The National 
Institutes of Health-supported Dialysis 
Access Consortium trial is under way, 
evaluating pharmacologic therapies to 
retard the endothelial and ﬁbromuscular 
hyperplasia that generates stenoses. Major 
trials are under way evaluating surgical 
correction as well as new stent designs. 
Novel PTA cutting and high-pressure 
balloons are being developed. Even more 
important is a shift from AV grafts, with 
their stenosis-prone vein graft anastomo-
sis, to the longer-lived native AV ﬁstulae, as 
exempliﬁed by the ‘ﬁstula ﬁrst’ initiative.
What is not controversial is that access 
to the circulation is the Achilles’ heel of 
dialysis therapy. It is the leading contrib-
utor to morbidity among our patients. 
Every new advance is welcomed. We still 
have a long way to go.
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Figure 1 | AV graft. PTFE, polytetrafluoroethylene. (Adapted from ref. 11.)
